Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feb. 15, Vol. 29, No. 4

    • Point of View

      • Overreacting to Perceived Risks
      • Henry I. Miller, M.D.
      • From rubber duckies and plastic bottles to pesticides used in agriculture, the world often seems full of lethal hazards. Many of these concerns are completely bogus, however, while most of the others represent only de minimis—that is, negligible—ris ... more »
    • Feature Articles

      • Boosting Potential LC/MS Operations
      • Nina Flanagan
      • Although mass spectrometry (MS) dates back to 1897, and high-performance liquid chromatography (LC) to the 1970s, scientists are still developing methods to enhance their capabilities. Rapid advancements in the pharmaceutical and biotechnology field ... more »
      • Honing In on Targeted Resequencing
      • Kathy Liszewski
      • Targeted resequencing is one of the fastest growing applications for next-generation sequencing technology. The ultimate goal is to look for causative mutations within discrete genomic loci in populations in order to enhance diagnostics and treatmen ... more »
      • Low-Volume Liquid Handling Gaining Favor
      • Gail Dutton
      • In the unending quest to do more with less, the biotech industry has embraced low-volume liquid handling, and is continuing to advance the tools and techniques that make it a laboratory mainstay. With microtiter well volumes often in the nanoliter r ... more »
    • Tutorials

      • Modeling Ensemble Powers Systems Biology
      • Colin Hill
      • We know the numbers by heart:  bringing a new drug to market requires, on average, 12–15 years and about $1 billion. And despite the record investment in R&D in 2007 ($58.8 billion), the development of new chemical entities (NCEs) was at an ... more »
    • Corporate Profile

      • PerkinElmer Retools Its Strategic Mission
      • Carol Potera
      • Starting this year, PerkinElmer is aligning its business to focus on two strategic areas—human health and environmental health. The new emphasis better defines the strategic mission of the company and, at the same time, improves how it communicates ... more »
    • BioMarket Trends

      • Sky Could Be the Limit for DNA Testing
      • Bruce Carlson
      • DNA testing represents a revolution postponed, perhaps, but one that is now clearly under way. After years of glowing predictions that didn’t immediately translate into change in clinical diagnostics, DNA testing has emerged fully from research into ... more »
    • Company Updates

      • Stratatech Builds on Cell Line Discovery
      • Carol Potera
      • While performing basic research on keratinocytes at the University of Wisconsin, Madison, Lynn Allen-Hoffmann, Ph.D., routinely obtained cells discarded from infant circumcision tissue and grew them in monolayer cultures. In an experiment to look ... more »
      • Recent Advances in NextGen Sequencing
      • Illumina just released new sequencing chemistry kits and complementary software for its Genome Analyzer system. These new products reportedly enable researchers to generate 40% more reads per run and extend read length to greater than 75 bp. Also ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »